In mid-March 2025, numerous experts and representatives from the pharmaceutical industry traveled to Milan for BIO Europe Spring, one of the largest and most important biotech conferences in Europe. Over 2,000 companies from 60 countries were represented at the renowned event, ranging from major global corporations to innovative start-ups. It was the ideal opportunity for InnoMedica to present itself in an international context and show how the company stands out in a dynamic industry. With 41 meetings in three days, InnoMedica's team put together a sporty agenda.
Among the highlights were the meetings with major pharmaceutical companies, which led to exciting discussions about potential partnerships. These meetings provided valuable insights into the needs of the industry and made it possible to forge new connections that will be important in the coming months and years.
In addition to the planned meetings, exciting spontaneous conversations also took place at our stand. In addition to their interest in the medicine bottles in the display case, visitors were also attracted by a classic Swiss souvenir: Lindor chocolate balls. These proved to be an ideal ice-breaker and led to spontaneous contacts.
At first glance, only the color concept seems to link the vials with the chocolate balls. With a little imagination, however, the latter served as a (very simplified) explanatory model for the basis of InnoMedica's medicines – liposomes. These are tiny spheres consisting of lipids (fats) that occur naturally in the human body. While the Lindor balls are filled with milk chocolate and salted caramel, the liposomes in the vials contain active pharmaceutical ingredients. By packaging them in liposomes, the active ingredients can be transported to their destination efficiently and in a targeted manner.
Why are such conferences important for young pharmaceutical companies?
It is crucial for up-and-coming companies to present themselves at international events in order to make their name and products known in the global pharma and biotech community. Conferences offer a platform for exchange with established companies and enable companies to expand their own network in the industry.
The interest that InnoMedica aroused among many of the discussion partners was particularly pleasing. Above all, the fact that the company has two drug candidates in clinical trials and its own GMP-certified production facility was met with astonishment and recognition. For a company of this size, this is anything but ordinary and underlines InnoMedica's commitment to meeting the highest quality standards and working independently.
Our participation in BIO Europe 2025 was therefore a complete success and we are looking forward to seeing how the new acquaintances develop.
